logo
UL Solutions and Eyesafe Collaborate to Advance Blue Light Protection

UL Solutions and Eyesafe Collaborate to Advance Blue Light Protection

Guided by the latest health research and insights from doctors, Eyesafe is introducing new industry requirements for displays and screen protection accessories. UL Solutions will verify product efficacy to the requirements on blue light emissions and circadian impact.
MINNEAPOLIS, Jan. 28, 2025 /PRNewswire/ -- Eyesafe, a global provider of blue light solutions and technology, announced at CES 2025 the launch of Eyesafe® Display Requirements 3.0 and Eyesafe® Accessory Requirements 3.0. These new programs set criteria for the consumer electronics and screen protection industries, establishing thresholds for high-energy blue light and color performance.
Eyesafe and UL Solutions have developed new industry methodologies to help verify marketing claims related to blue light reduction and color performance.
Eyesafe® Display Requirements 3.0
Defines key criteria, including blue light toxicity, circadian stimulus, color gamut and color temperature, to measure a product's blue light emissions associated with visual comfort and sleep disruption, while ensuring display color performance.
RPF® (Radiance Protection Factor): Measures protection from blue light that can impact eyes, focusing on the blue light hazard, peaking between 435-440 nanometers (nm). 1 The higher the score (on a scale of 0-100), the better the blue light reduction. A score of 35 or higher is needed to earn a marketing claim verification.
CPF (Circadian Protection Factor): Focuses on reducing blue light that can affect sleep and circadian rhythms (480-500 nm).2 Higher scores indicate less circadian disruption, with 35 or higher needed to earn a marketing claim verification.
Color Performance: Determines accuracy and vividness of display colors.
Eyesafe® Accessory Requirements 3.0
Defines key criteria tailored to display type (LCD/LED or OLED) to measure a product's blue light emissions associated with visual comfort and/or circadian impact, while ensuring display color performance.
For LCD/LED Screens (common in laptops and monitors): The assessment methodology focuses on RPF, or level of blue light filtration across the wavelengths that may impact eye health (435-440 nm)1 and blue light toxicity reduction. The higher the score (on a scale of 0-100), the better the blue light reduction. A score of 20 or higher is needed to earn a marketing claim verification.
For OLED Screens (common in smartphones): The assessment methodology targets CPF, or level of blue light filtration across the wavelengths that can affect melatonin production and circadian rhythms (peak 480-500 nm)2 and change in circadian impact (380-780 nm). Higher scores indicate less circadian disruption, with 20 or higher needed to earn a marketing claim verification.
Color Accuracy: All products must meet criteria for correlated color temperature and luminance to ensure display colors remain vibrant (accommodations provided for privacy screen protection).
Eyesafe Display Requirements 3.0 and Eyesafe Accessory Requirements 3.0 provide important guidelines to assess that digital devices and accessories not only provide effective blue light protection but also deliver a great visual experience. Products are tested and verified by UL Solutions, upon which manufacturers receive the UL Marketing Claim Verification Mark, helping consumers identify products that deliver on performance claims. For more information, visit eyesafe.com/UL-verification.
Introducing Eyesafe® CPF60 Technology for Mobile Accessories
At CES 2025, Eyesafe also debuted its patented Eyesafe CPF60 technology for mobile screen protectors. This advanced solution targets blue light in the 480-500 nm range to mitigate circadian rhythm disruption2 while also supporting visual comfort and display color accuracy.
A groundbreaking study by SleepScore Labs on Eyesafe CPF60 technology revealed:3
79% of users reported improved sleep
76% of users felt more refreshed upon waking
89% of users observed reduced eye strain
Users said their productivity increased by 32%
These findings, based on self-reported survey results, underscore the potential consumer benefits of Eyesafe CPF60 and showcase its ability to positively impact users' daily lives.
The Eyesafe programs represent an important step forward in blue light protection. By combining forward-thinking display and accessory requirements with innovation like Eyesafe CPF60 technology, manufacturers are equipped with guidelines and technology to address blue light's potential impact on eye health and sleep. These advancements reflect a shared commitment to supporting consumer wellbeing through science-based solutions. To learn more about these programs, visit eyesafe.com/UL-verification.
1. Spectral Weighting Factors for Blue-Light Hazard as published by the International Commission on Non-Ionizing Radiation Protection (ICNIRP) in 2013 and the American National Standard Institute (ANSI) in 2015.
2. The International Committee on Illumination's (CIE) published and universally recognized standard CIE S 026/E:2018.
3. Based on a 2024 study conducted by SleepScore Labs. Individual results may vary. This information is not a substitute for professional medical advice. Consult a healthcare professional for any health condition.
ABOUT EYESAFE
Eyesafe Inc. is the world leader in blue light management, including display technology, standards, certification, and accessory solutions. With an expansive portfolio of intellectual property, the company employs a world-class team of eye doctors, engineers, and scientists with decades of experience in electronics, display materials, light management, optometry, and ophthalmology. The Eyesafe brand is trusted by consumers and integrated in millions of digital devices from Dell, HP, Lenovo, LG, ZAGG and more. Eyesafe is recognized by Inc. 5000 as one of the fastest growing private companies in America and by the Minneapolis/St. Paul Business Journal as the #1 Fastest Growing Company in Minnesota. Learn more at eyesafe.com.
+1 (612) 704.1551

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Yahoo

time27 minutes ago

  • Yahoo

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.

Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Presents New Data on the Benefits of ALYFTREK

Yahoo

time27 minutes ago

  • Yahoo

Vertex Presents New Data on the Benefits of ALYFTREK

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Chick-fil-A launches new BBQ sandwich for a limited time in Jacksonville
Chick-fil-A launches new BBQ sandwich for a limited time in Jacksonville

Yahoo

time35 minutes ago

  • Yahoo

Chick-fil-A launches new BBQ sandwich for a limited time in Jacksonville

Chick-fil-A's Creamy BBQ Sandwich comes to Jacksonville for a limited time starting June 9 through July 19. >>> STREAM ACTION NEWS JAX LIVE << >> STREAM ACTION NEWS JAX LIVE <<< The Creamy BBQ Chicken Sandwich can be delivered on the Chick-fil-A® App or online. However, it cannot be catered. [DOWNLOAD: Free Action News Jax app for alerts as news breaks] Also, members will not be able to redeem points for this sandwich, but can still receive points with their purchase. [DOWNLOAD: Free Action News Jax app for alerts as news breaks] [SIGN UP: Action News Jax Daily Headlines Newsletter] Click here to download the free Action News Jax news and weather apps, click here to download the Action News Jax Now app for your smart TV and click here to stream Action News Jax live.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store